TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02508129

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet
Description: SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
Study: NCT01971437

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystodistension & Cystoscopy
Description: Women with refractory OAB receiving Cystoscopy and cystodistension

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystodistension & Cystoscopy
Description: Women with refractory OAB receiving Cystoscopy and cystodistension
Study: NCT03150407

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR101 Device (Efficacy)
Description: Self-insertion of VR101 Device for 7 days, followed by replacement with a fresh VR101Device, until 4 each Devices have been used for 7 days each, with total consecutive device use equal to 28 days

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control Ring
Description: Self-insertion of Sham Ring for 7 days, followed by replacement with a fresh Sham Ring, until 4 each Sham Rings have been used for 7 days each, with total consecutive Sham use equal to 28 days

Intervention type: DEVICE
Group type: OTHER
Intervention: VR101 Device (Safety)
Description: Following the 4-week use of shams and a 3-week washout period participants randomized to the Safety Study will use a new VR101 device every 7 days for 13 consecutive weeks.
Study: NCT02053337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self adhesive foam dressing
Description: Self adhesive foam dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self adhesive foam dressing
Description: Self adhesive foam dressing
Study: NCT00735618

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Relaxation
Description: Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
Study: NCT00428116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: Combination first line antiretrovirals as previously described.
Study: NCT03629197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communication skills training
Description: Intervention components include an 8-10 minute instructional video, a pocket card and pamphlet, and 2 standardized patient visits with role-play and feedback by the standardized patient

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention control
Description: Physician will review materials based on CDC opioid prescribing guidelines.
Study: NCT02564887

Intervention type: DEVICE
Group type: OTHER
Intervention: Iowa Oral Performance Instrument
Description: the IOPI device is being used to increase tongue strength and endurance

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iowa Oral Performance Instrument
Description: the IOPI device is being used to increase tongue strength and endurance
Study: NCT02341391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Low dose)
Description: 3.0 x 10\^6 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(Medium dose)
Description: 1.0 x 10\^7 cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C(High dose)
Description: 3.0 x 10\^7 cells
Study: NCT04787679

Intervention type: PROCEDURE
Intervention: Hip replacement surgery
Description: After hip replacement surgery the sponsor obtains femoral head samples for the study

Intervention type: PROCEDURE
Intervention: Hip replacement surgery
Description: After hip replacement surgery the sponsor obtains femoral head samples for the study
Study: NCT03593538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose filler in gel capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sucrose filler in gel capsules
Study: NCT01012518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-guided PCT
Description: PCT performed with the guidance of a camera-embedded ETT wired to a monitor
Study: NCT01575665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partial Rebreathing Mask
Description: Inducing normal CO2 for two hours a day for four weeks
Study: NCT01859910

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: compression and scrub of lid margin
Description: compression and scrub of lid margin for 5 circles before cataract surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine preparation for cataract

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine preparation for cataract
Study: NCT03909295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: Starting dose was either 50 mg b.i.d. or 100 mg b.i.d. largely depending on the last dose level taken by the patient at the time of completing PARAGON-HF and patient condition. The dose level was gradually up-titrated with the goal of reaching the target dose of 200 mg b.i.d. as soon as tolerated by the patient
Study: NCT01951742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active
Study: NCT01763320

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracranial stenting group
Description: all the participants in this group will be performed with intracranial stenting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical group
Description: all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
Study: NCT02109874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404 (mcg H4/nmol IC31)
Description: Dose escalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404 (mcg H4/nmol IC31)
Description: Dose escalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404 (mcg H4/nmol IC31)
Description: Dose escalation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-404 (mcg H4/nmol IC31)
Description: Dose escalation

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl
Study: NCT03723174

Intervention type: BEHAVIORAL
Intervention: Oral Health Educational Program
Description: proper introduction to brushing techniques, dietary recommendations and importance of visiting the dentist
Study: NCT02535286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbralisib
Description: A once daily oral agent

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ublituximab
Description: IV anti-CD20 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TG-1501
Description: IV immunotherapy for cancer
Study: NCT03391726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CART-19 cells
Description: CART-19 cells treat
Study: NCT02264860

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Zinc and SAMe
Description: The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
Study: NCT00567684

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Urography (CTU)
Description: CTU performed at least a day before or after the IVU procedure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intravenous Urography (IVU)
Description: A routine IVU procedure performed prior to or after CTU.
Study: NCT00658047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-1504
Description: Comparison of different doses of CH-1504
Study: NCT03624426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated Somatosensory Evoked Potential device (EPAD@)
Description: After commencement of general anesthesia and during patient positioning, stimulating sensors will be applied to patient wrists and a recording sensor is applied at base of neck posteriorly (at C5 level), forehead and the bilateral wrists. The monitoring will be continued throughout the surgery.
Study: NCT02675192

Intervention type: OTHER
Intervention: Proof cohort : muscular assessment
Description: Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
Study: NCT01951742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1401
Description: Active

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle
Study: NCT02066740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EverFlex™ stent with Entrust™ delivery system
Study: NCT02201706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-electrocoagulation retinectomy
Description: a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.~All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.~Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process.
Study: NCT01014520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin , Amitriptyline
Description: Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin , Amitriptyline
Description: Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery
Study: NCT03564847

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus
Description: LTP+Dads is a 12 - session group integrated parenting intervention: i.e LTP (Learning through Play) which includes a pictorial calendar, consisting of stages of child development from birth to 3 years. It includes parent-child play and other activities that promote parental involvement, learning, and attachment. In each stage, there are five areas of child development: sense of self, physical, relationships, understanding, and communication. All areas are written in simple, low-literacy language.~Second component of intervention is CBT adapted from Jeanne Miranda manual (Group CBT for Depression, group leaders guide book-2006) focusing on the three areas: thoughts and your mood, activities and your mood, people interaction and your mood.~Third component of intervention is content taken from Ed Bader's manual (Focus on Fathers) includes importance of fathers in child development, stress management at work and home, budgeting, anger management, conflict resolution and time management.
Study: NCT00658047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-1504
Description: Comparison of different doses of CH-1504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CH-1504
Description: Comparison of different doses of CH-1504
Study: NCT02707081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous normal saline
Description: Normal saline in a volume equivalent to that used in intravenous lidocaine group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline
Description: Normal saline in a volume equivalent to that used in intravenous lidocaine group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal normal saline
Description: Patients received 00 ml of saline intraperitoneally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraperitoneal normal saline
Description: Patients received 00 ml of saline intraperitoneally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intraperitoneal Lidocaine
Description: Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Lidocaine
Description: Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
Study: NCT00658047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (MTX)
Description: 10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
Study: NCT03464630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mom & Baby Net
Description: CBT skills based mobile intervention targeting maternal depression and sensitive responsive parenting practices for optimizing infant social-communication promotion and provision of community resources and referral

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Depression & Developmental Awareness System
Description: Supportive, person-centered mobile intervention targeting maternal awareness of maternal depression symptoms, infant developmental milestones, and provision of community resources and referral (active control condition)
Study: NCT04159272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Training
Description: The programme consists of 8 90-min sessions held once a week for 8 consecutive weeks. Each session consists of guided experiential mindfulness exercises, sharing of experiences of these exercises, reflections in small groups, psycho-education, and review of home practices. An overview of the core elements in each session is given in Van der Gucht et al. (2017). The in-class MT programme will be supported with a mindfulness for adolescents smartphone application to support practice at home.~The curriculum is available in an open source platform. The training is supported by the use of homework assignments and audio material. The programme has already been piloted and reviewed in an expert group of mindfulness trainers and scientists working with youth in mental health care (Van der Gucht et al., 2017) and in refugee centres (Van der Gucht et al., 2019). The MT will be delivered by certified trainers (\>3 years of experience). During the trial they will receive regular supervision.
Study: NCT03445728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: After randomization, receive primary PCI and standard therapy, 12mg Nicorandil iv. just before ballooning or stenting, then keep Nicorandil 6mg/h ivgtt. up to 24h
Study: NCT00489827

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous infusion of saline
Description: Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous glutamate infusion
Description: Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
Study: NCT04080544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AV-1451
Description: The subject will receive up to a target dose of 370 megabecquerel (MBq) as a single IV bolus of \[18F\]AV-1451.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Approximately 80 minutes after injection subjects will be placed in the UTSW PET/CT scanner for a 20-minute brain scan.
Study: NCT03510390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg, oral, twice daily, 9-14 days
Study: NCT02192190

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - SC
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - SC
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Administered orally
Study: NCT03645239

Intervention type: PROCEDURE
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.

Intervention type: PROCEDURE
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
Study: NCT02422537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Unmodified wheat bran

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bran with reduced particle size
Study: NCT02381132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norco 7.5mg/325
Study: NCT02422537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Destarched pericarp-enriched wheat bran

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: No wheat bran fraction
Study: NCT03258762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrimethamine
Description: Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium folinate
Description: Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
Study: NCT04352686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: Administration of buspirone to assess esophageal sensitivity
Study: NCT03445728

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomization, receive primary PCI and standard therapy, just like the intervension group also iv. just before ballooning or stenting, then keep ivgtt. up to 24h
Study: NCT00741494

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PICSI dish
Description: Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICSI dish
Description: Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
Study: NCT01107600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate implant and socket preservation
Description: Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.